Cardax Inc CDXI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.81 / $1.00
- Market Cap
- $0.80
- Volume/Avg
- 2,037 / 1,958
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cardax Inc is a life sciences company engaged in the development of marketing, and distribution of consumer health products in the United States. The firm's platform has applications in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. It is focused on the development of astaxanthin technologies. The group's product ZanthoSyn is marketed as a novel astaxanthin dietary supplement. Astaxanthin is a clinically studied ingredient with a safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. Geographically, it generates maximum revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 12
- Website
- http://www.cardaxpharma.com
Valuation
|
Metric
|
CDXI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CDXI
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.09 |
Interest Coverage | −1.29 |
Quick Ratio
CDXI
Profitability
|
Metric
|
CDXI
|
|---|---|
Return on Assets (Normalized) | −295.56% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CDXI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tyyznwzlm | Pdww | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bnnpxpq | Vtcfpx | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lsjcpytr | Ftxygb | $98.8 Bil | |
MRNA
| Moderna Inc | Btbygvxsw | Fsf | $38.8 Bil | |
ARGX
| argenx SE ADR | Zdsblzwzv | Zwr | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Bgrrgnpv | Lkwjt | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ykpgqtffn | Cjghby | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vlsfvpz | Fggnhf | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mggwxphzr | Vnbppj | $12.4 Bil | |
INCY
| Incyte Corp | Xzpvjnq | Zhbvzw | $11.9 Bil |